Preclinical Study Identifies AMPK-Sirtuins Axis as Target to Reverse Stress-Induced Inflammaging

A mouse model study shows that chronic mild stress accelerates systemic inflammaging and tissue-specific mitochondrial damage, both of which are mitigated by NMN and the Bazi Bushen formula via AMPK-Sirtuins pathway activation.

Researchers utilized a 12-month unpredictable chronic mild stress (UCMS) mouse model to evaluate how chronic stress exacerbates systemic inflammation and tissue damage.

The stress model resulted in a systemic reduction of lymphocytes, expansion of myeloid cells, and significant epigenetic dysregulation and mitochondrial dysfunction in the lungs and kidneys.

Both beta-nicotinamide mononucleotide (NMN) and the traditional Chinese medicine formulation Bazi Bushen (BZBS) successfully alleviated these stress-induced aging phenotypes in vivo.

Bioactive compounds from BZBS constituents (Schisandra chinensis and Cnidium monnieri) were shown to restore immune homeostasis and improve mitochondrial function via the activation of AMPK-SIRT-PGC-1alpha signaling.

The study provides a molecular map of how chronic psychological or physical stress translates into accelerated physiological aging (inflammaging) and multi-organ damage.

It provides comparative validation for NMN alongside multi-constituent traditional formulations, showing that both can address the complex, systemic nature of stress-induced cellular decline.

The results reinforce the importance of early intervention in stress-induced pathways to prevent the onset of chronic, age-related diseases.

The identification of AMPK-Sirtuins activation as a primary pathway for reversing stress-induced tissue damage supports the clinical rationale for pipelines targeting cellular energy sensors and metabolic health.

The study's focus on reversing myeloid cell expansion and restoring immune homeostasis aligns with emerging market interests in immune-reprogramming cell therapies.

Mitochondrial dysfunction being flagged as a prominent stress response across critical organs highlights the relevance of companies advancing mitochondrial transplantation and repair technologies.

Further translational studies to determine whether AMPK-SIRT-PGC-1alpha pathway activation can reverse chronic stress phenotypes in clinical human cohorts.

Development of standardized, single-agent therapies derived from the active constituents of Schisandra chinensis and Cnidium monnieri.